K.Y. Thong, M.L. Cull,  R.E.J. Ryder, C. Walton, on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
Wiley online:
Diabetic Medicine 2012; 29(5): 690-692
Full paper (On audit subwebs - ABCD members and audit contributors only):
Diabetic Medicine 2012; 29(5): 690-692    

All contributors are listed

Bob Ryder and Ken Thong, on behalf of the ABCD nationwide exenatide and nationwide liraglutide audit contributors. Findings from the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
Full paper (On audit subwebs - ABCD members and audit contributors only):
In Hot topics in diabetes, Vora J, ed. Synergy, London, 2012        

All contributors are listed

K.Y. Thong,  C. Walton, R.E.J. Ryder, on behalf of the ABCD nationwide liraglutide audit contributors. Safety and efficacy of liraglutide 1.2mg in patientswith mild and moderate renal impairment:the ABCD nationwide liraglutide audit.
Practical Diabetes 2013; 30(2): 71-76
Full paper (On liraglutide audit subweb - ABCD members and audit contributors only):
Practical Diabetes 2013; 30(2): 71-76 

All contributors are listed 

 REJ Ryder, KY Thong, AD Blann, SM Phillips, ND Barwell, CJG Kelly, C Semple, ML Cull, P Sen Gupta for the ABCD nationwide liraglutide audit contributors. Liraglutide pancreatitis: The ABCD nationwide liraglutide audit.

Br J Diabetes Vasc Dis 2013; 13: 253-259
Full paper:
Br J Diabetes Vasc Dis 2013; 13: 253-259

All contributors are listed

 R. E. J. Ryder, P. Sen Gupta, K. Y. Thong on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis—what happens next? A personal viewpoint

Diabetic Medicine 2013; 30(12): 1510-1511
Full paper (ABCD members and audit contributors only):
Diabetic Medicine 2013; 30(12): 1510-1511

All contributors are listed 

KY Thong, P Sen Gupta, ML Cull, KA Adamson, DS Dove, SV Rowles, S Tarpey, C Duncan, J Chalmers, R Harper, P McDonald, U Brennan, C Walton, REJ Ryder on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes

Br J Diabetes 2014; 14: 52-59
Full paper:
Br J Diabetes 2014; 14: 52-59
 All contributors are listed

 K.Y. Thong, P Sen Gupta, A.D. Blann, R.E.J. Ryder  on behalf of the ABCD nationwide liraglutide audit contributors. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes

Diabetes Research and Clinical Practice 2015, 109: 124-129
Full paper (ABCD members and audit contributors only):
Diabetes Research and Clinical Practice 2015, 109: 124-129
 All contributors are listed

 K.Y. Thong, B.M. Mcgowan, T. Htay, A. Pernet, C. Kelly, C. Rajeswaran, J. Howell, C. Duncan, B. Inkster, L. Buchanan, S. Kassim, R. Nayer, N.D. Barwell, C. Walton, R.E.J Ryder, ABCD Nationwide Liraglutide Audit contributors. Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit.

Br J Diabetes 2015; 15(4): 169-172
Full paper: Br J Diabetes 2015; 15(4): 169-17

All contributors are listed

Thomas SJ Crabtree, Susannah Rowles, Stephanie Tarpey, Adele Kennedy, John Chalmers, Rahul Nayar, Amanda Lee, Ken Darzy, Peter Winocour, John Lindsay, Iskandar Idris, Ken Y Thong, Piya Sen Gupta, Amar Puttanna, Pranav Kumar, Robert EJ Ryder, On behalf of ABCD Nationwide Audit Contributors  Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit.

Abstract BJD 2019, Vol 19, No 2, 227

Full Paper

BJD 2019, Vol 19, No 2, 118-124

All contributors are listed

DUK Annual Professional Conference, London, April 1, 2011

ADA Scientific Update Satellite Meeting, San Diego, June 26 2011

ADS/ADEA Annual Scientific Meeting, Perth, August 31, 2011

EASD Scientific Update Satellite Meeting, Lisbon, September 14 2011

IDF Scientific Update Satellite Meeting, Dubai, December 6 2011

IDF Main Meeting, Dubai, December 6 2011

DUK Annual Professional Conference, Manchester, March 13, 2013

Australian Diabetes Society 2011: Ken Y Thong and Bob Ryder on behalf of the ABCD nationwide exenatide and liraglutide audits contributors. Response of HbA1c and weight against time in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. 2011 ADS/ADEA Annual Scientific Meeting Programme, Abstract 062

EASD Lisbon 2011: R.E.J. Ryder, K.Y. Thong, M.L. Cull, A.P. Mills, C. Walton, ABCD nationwide exenatide and liraglutide audit contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetologia 2011, Vol.54 Supplement1: S326

EASD Lisbon 2011: C. Walton, R.E.J. Ryder, M.L. Cull, A.P. Mills, K.Y. Thong, ABCD nationwide exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetologia 2011, Vol.54 Supplement1: S326

ABCD Autumn Meeting, London, 2011: CE Walton, REJ Ryder, ML Cull, AP Mills, KY Thong, , on behalf othe ABCD nationwide exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes at 6 months in Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit. Poster 4a, ABCD Autumn Meeting 2011

ABCD Autumn Meeting, London, 2011: REJ Ryder, KY Thong, ML Cull, A P Mills C Walton. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Poster 4b, ABCD Autumn Meeting 2011

IDF Dubai 2011: R.E.J. Ryder, K.Y. Thong, M.L. Cull, A.P. Mills, C. Walton, ABCD nationwide exenatide and liraglutide audit contributors. Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits. Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (oral presentation)

IDF Dubai 2011: K. Thong, K. Darzy, M.L. Cull, A.P. Mills, R.E.J. Ryder, ABCD nationwide exenatide and liraglutide audit contributors. Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (poster presentation)

IDF Dubai 2011: K. Thong, R.E.J. Ryder, C. Walton, ABCD nationwide exenatide and liraglutide audit contributors. Factors associated with HbA1c and weight changes in the Association of British Clinical Diabetologists nationwide GLP-1 agonists audits.
Abstract Book, 21st World Diabetes Congress, IDF, Dubai, UAE, 4-8 December 2011. (poster presentation)

ADA Philadelphia 2012: KEN Y. THONG, CHRISTOPHER WALTON, ROBERT EJ. RYDER, ABCD NATIONWIDE LIRAGLUTIDE AUDIT CONTRIBUTORS. Insulin Necessity is Better than Diabetes Duration in Predicting Liraglutide Treatment Response: The Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit. Diabetes 2012; 61 (Suppl. 1): A266

ADA Philadelphia 2012: KEN Y. THONG, CHRISTOPHER WALTON, ROBERT EJ. RYDER, ABCD NATIONWIDE LIRAGLUTIDE AUDIT CONTRIBUTORS. Liraglutide is Safe and Effective in Mild or Moderate Renal Impairment: The Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit. Diabetes 2012; 61 (Suppl. 1): A287

EASD Berlin 2012: R.E.J. Ryder, P. Sen-Gupta, K.Y. Thong, ABCD nationwide liraglutide audit contributors. Liraglutide is effective across a range of obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Diabetologia 2012, Vol.55 Supplement1: S330

DUK Manchester 2013; Diabetes Research Award Session. Sen Gupta P, Thong KY, Cull M, Winocour P, Ryder REJ on behalf othe ABCD nationwide exenatide and liraglutide audit contributors. Does liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 Diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Diabetic Medicine 2013. 30 (Suppl 1): 3.

ABCD Spring Meeting, Solihull, 2013, abstract 1: P Sen Gupta, KY Thong, REJ Ryder, on behalf othe ABCD nationwide exenatide and liraglutide audit contributors. Combined insulin and liraglutide therapy is associated with metabolic improvement and reduction in insulin dose in commonly prescribed insulin regimens: an ABCD liraglutide audit analysis. Poster 1, ABCD Spring Meeting 2013

ABCD Spring Meeting, Solihull, 2013, abstract 15:  REJ Ryder, KY Thong, A Blann, S Phillips, N Barwell, C Kelly, C Semple, S Struthers, P Sen Gupta, on behalf othe ABCD nationwide exenatide and liraglutide audit contributors. Liraglutide and acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Poster 15 (late breaking), ABCD Spring Meeting 2013

ADA San Francisco 2014: P Sen Gupta, KY Thong, C Walton, REJ Ryder on behalf of the ABCD nationwide liraglutide audit contributors.  Combined Liraglutide-Insulin Therapy Is Associated with Metabolic Improvement and Insulin Dose Reduction in Commonly Prescribed Insulin Regimens. Diabetes 2014; 63 (Suppl. 1): 1023-P3

EASD Berlin 2018 C. Walton; S. Kassim; R. Harper; P. McDonald; U. Brennan; J. Harding; T. Htay; R. Nayar; A. Pernet; S. Rowles; K. Adamson; K.Y. Thong; R.E.J. Ryder. Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine). Diabetologia 2018, Vol.61 Supplement1: Abstract 747